Global call for applications to take part in a Boehringer Ingelheim Office Hours dedicated to Hearing Loss, in partnership with the Hearing Medicines Discovery Syndicate, is now open for interested innovators from academia and early/pre-seeds biotechs working on the discovery of treatments for hearing loss and tinnitus.
If you are working on an innovative drug discovery programme (including gene therapy and therapeutic technologies) for hearing loss and tinnitus and you want to access pharmaceutical expertise and guidance on the tools and strategies you may need to take your research forward, apply now!
Your project will be able to benefit from industry-leading insight as well as research and development experience to advise on how to reduce risks, increase efficiency, and maximise the chance of success in securing funding or the next milestone.
Each innovator selected to participate in the Boehringer Ingelheim Office Hours dedicated to Hearing Loss will have an individual, 1-hour session with the multidisciplinary team of R&D experts from Boehringer Ingelheim, with translational pharmacology, preclinical and clinical, PK/PD and medical expertise, as well as venture fund and commercial expertise.
The Boehringer Ingelheim R&D experts will also be able to provide guidance on a range of aspects, including clinical development, research strategy and planning, and commercial potential.
The Office Hours dedicated to Hearing Loss is part of the Boehringer Ingelheim Grass Roots mentoring initiative.
Before submitting your application, please ensure that you have read and understood our Terms and Conditions and the relevant data privacy policies.
Applications must be submitted by the closing date: April 17, 2020 23:59 UK time; late applications will not be considered.